Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Artivion Inc

Healthcare US AORT

20.68USD
0.55(2.73%)

Last update at 2026-06-23T20:00:00Z

Day Range

20.0920.71
LowHigh

52 Week Range

23.0448.25
LowHigh

Fundamentals

  • Previous Close 20.13
  • Market Cap1881.64M
  • Volume568709
  • P/E Ratio184.76
  • Dividend Yield-%
  • EBITDA53.80M
  • Revenue TTM441.33M
  • Revenue Per Share TTM9.73
  • Gross Profit TTM 284.23M
  • Diluted EPS TTM0.21

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 14.78M -7.51400M -21.58600M -14.98400M -14.82700M
Minority interest - - - - -
Net income 9.77M -13.35900M -30.69000M -19.19200M -14.83400M
Selling general administrative 226.49M 190.68M 183.50M 157.44M 169.77M
Selling and marketing expenses - 1.70M 1.90M - -
Gross profit 270.45M 248.78M 229.18M 202.52M 197.51M
Reconciled depreciation 22.46M 24.20M 22.69M 22.44M 23.98M
Ebit 26.75M 26.76M 3.71M 3.24M -13.86300M
Ebitda 49.20M 50.97M 26.79M 25.68M 10.11M
Depreciation and amortization 22.46M 24.20M 23.08M 22.44M 23.98M
Non operating income net other - - - -2.96100M -6.05700M
Operating income 26.75M 38.87M 5.74M 3.24M -13.86300M
Other operating expenses 414.58M 349.66M 348.26M 307.59M 306.64M
Interest expense 26.58M 34.28M 25.30M 18.22M 16.89M
Tax provision 5.01M 5.84M 6.83M 4.21M 0.00700M
Interest income 0.76M 1.47M 0.74M 0.15M 0.08M
Net interest income -25.81900M -32.81000M -23.68500M -18.07700M -16.80800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.01M 5.84M 9.10M 4.21M 0.00700M
Total revenue 441.33M 388.54M 354.00M 313.79M 298.84M
Total operating expenses 243.71M 209.91M 223.43M 196.32M 205.32M
Cost of revenue 170.88M 139.76M 124.83M 111.27M 101.32M
Total other income expense net -11.96500M -46.38800M -27.32800M -18.22400M -0.96400M
Discontinued operations - - - - -
Net income from continuing ops 9.77M -13.35900M -24.54600M -19.19200M -14.83400M
Net income applicable to common shares - - - -19.19200M -14.83400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 884.80M 789.10M 792.40M 762.80M 793.05M
Intangible assets 156.50M 156.38M 172.23M 182.65M 201.50M
Earning assets - - - - -
Other current assets 42.54M 70.96M 65.61M 17.55M 57.61M
Total liab 436.56M 512.90M 510.62M 478.47M 492.32M
Total stockholder equity 448.23M 276.20M 281.78M 284.33M 300.73M
Deferred long term liab - - - 29.97M 34.75M
Other current liab 80.14M 40.63M 35.28M 7.74M 1.08M
Common stock 0.49M 0.43M 0.43M 0.42M 0.41M
Capital stock 0.49M 0.43M 0.43M 0.42M 0.41M
Retained earnings -51.49800M -61.26600M -47.90700M -17.21700M 1.98M
Other liab - - - 77.39M 90.64M
Good will 254.09M 240.96M 247.34M 243.63M 250.00M
Other assets - - - 8.65M 10.62M
Cash 64.91M 53.46M 58.94M 39.35M 55.01M
Cash and equivalents - - - - -
Total current liabilities 101.56M 66.82M 57.86M 49.67M 44.95M
Current deferred revenue - - 3.84M 24.50M 28.17M
Net debt 227.13M 308.80M 299.40M 317.48M 307.03M
Short term debt 5.38M 5.29M 5.43M 5.43M 5.31M
Short long term debt - 0.20M 1.45M 1.61M 1.63M
Short long term debt total 292.04M 362.26M 358.34M 356.83M 362.04M
Other stockholder equity 501.96M 361.96M 341.27M 322.74M 308.23M
Property plant equipment - - - 38.67M 83.23M
Total current assets 303.55M 290.08M 280.67M 247.33M 247.70M
Long term investments - - - - -
Net tangible assets - - - -141.94900M -150.76800M
Short term investments - - - - -
Net receivables 103.68M 85.89M 74.14M 69.58M 58.10M
Long term debt 215.11M 314.15M 305.53M 306.50M 307.49M
Inventory 92.43M 79.77M 81.98M 74.48M 76.97M
Accounts payable 16.04M 17.97M 13.32M 12.00M 10.39M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.71900M -24.92700M -12.01000M -21.60900M -9.88700M
Additional paid in capital - - - - -
Common stock total equity - - - 0.42M 0.41M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -17.21700M 1.98M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 69.77M 24.48M 8.89M 7.34M 8.27M
Deferred long term asset charges - - - - -
Non current assets total 581.25M 499.02M 511.73M 515.46M 545.36M
Capital lease obligations 42.50M 47.91M 51.36M 48.72M 52.92M
Long term debt total - - - 306.50M 307.49M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -28.18800M -0.50100M -10.71500M 5.66M
Change to liabilities - - - -1.95800M -1.89300M
Total cashflows from investing activities -42.04100M -28.18800M -0.50200M -10.71500M 5.66M
Net borrowings -2.46000M -0.35800M -5.30300M -2.75300M -3.08500M
Total cash from financing activities 13.03M 2.20M 0.86M -1.63900M -12.22300M
Change to operating activities - - - -2.23400M -1.40400M
Net income 9.77M -13.35900M -30.69000M -19.19200M -14.83400M
Change in cash 11.45M -5.47700M 19.59M -15.65900M -6.94800M
Begin period cash flow 53.46M 58.94M 39.35M 55.01M 61.96M
End period cash flow 64.91M 53.46M 58.94M 39.35M 55.01M
Total cash from operating activities 38.13M 22.24M 18.82M -5.15300M -2.58500M
Issuance of capital stock - - - - -
Depreciation 22.46M 24.20M 23.08M 22.44M 23.98M
Other cashflows from investing activities -3.00000M -17.00000M 6.93M -1.69900M -0.24900M
Dividends paid - - - - -
Change to inventory -15.27700M -6.13700M -14.36000M -8.40400M -18.37500M
Change to account receivables -7.26900M -15.39500M -4.05000M -13.34000M -11.56000M
Sale purchase of stock 0.00000M 0.00000M -0.55900M -1.79500M -1.91400M
Other cashflows from financing activities 2.42M -3.16700M 4.20M -0.45900M -7.22400M
Change to netincome - - - 5.73M 21.50M
Capital expenditures 39.04M 11.19M 7.43M 10.71M 13.09M
Change receivables - - - -13.34000M -11.56000M
Cash flows other operating - - - 9.57M 11.90M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -17.50700M -9.14800M
Change in working capital -22.16100M -17.24300M -16.19300M -25.93600M -33.23200M
Stock based compensation 24.39M 14.24M 14.42M 12.34M 10.71M
Other non cash items 3.64M 15.90M 29.59M 6.91M 15.26M
Free cash flow -0.91100M 11.05M 11.39M -15.86800M -15.67600M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AORT
Artivion Inc		 0.55 2.73% 20.68 184.76 62.89 4.26 4.20 4.70 32.50
ABT
Abbott Laboratories		 2.70 3.07% 90.53 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 5.31 1.74% 310.00 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 1.36 1.72% 80.63 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 1.27 2.86% 45.60 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Artivion Inc

1655 Roberts Boulevard NW, Kennesaw, GA, United States, 30144

Key Executives

Name Title Year Born
Mr. James Patrick Mackin Chairman, Pres & CEO 1967
Mr. David Ashley Lee CPA, CPA Exec. VP, COO & CFO 1965
Ms. Jean F. Holloway Esq. Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. 1957
Mr. John E. Davis Sr. VP of Global Sales & Marketing 1965
Dr. Marshall S. Stanton M.D. Sr. VP of Clinical Research & Chief Medical Officer 1957
Ms. Amy D. Horton CPA, CPA VP & Chief Accounting Officer 1970
Mr. Matthew A. Getz VP of HR 1969
Mr. Dennis B. Maier Sr. VP of Operations 1974
Joshua Wells Sr. Director of Bus. Devel. NA
Mr. James Patrick Mackin Chairman, President & CEO 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions